| The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART |
Recruiting |
HIV/AIDS |
NCT03980665 |
| Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma |
Recruiting |
Neuroblastoma |
NCT03503864 |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia |
Recruiting |
Acute Promyelocytic Leukemia |
NCT03624270 |
| Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide |
Active, not recruiting |
Chronic Graft-Versus-Host Disease|Immune System Diseases |
NCT02966301 |
| Trisenox® in Women With Metastatic Endometrial Cancer |
Terminated |
Endometrial Carcinoma |
NCT01184053 |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI |
Unknown status |
Non-small Cell Lung Cancer |
NCT02066870 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Withdrawn |
Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia |
NCT01835288 |
| Study of Arsenic Trioxide in Small Cell Lung Cancer |
Completed |
Lung Cancer|Cancer of Lung|Pulmonary Cancer|Pulmonary Neoplasms|Carcinoma, Small Cell |
NCT01470248 |
| Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma |
Completed |
Basal Cell Carcinoma of the Skin|Recurrent Skin Cancer |
NCT01791894 |
| Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia |
Not yet recruiting |
Acute Promyelocytic Leukemia |
NCT03751917 |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC |
Unknown status |
Carcinoma, Hepatocellular |
NCT02018757 |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) |
Not yet recruiting |
Myelodysplastic Syndromes|P53 Mutation |
NCT03377725 |
| Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma |
Unknown status |
Carcinoma, Hepatocellular |
NCT01861912 |
| Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) |
Terminated |
Systemic Lupus |
NCT01738360 |
| Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy |
Terminated |
Metastatic Melanoma |
NCT00571116 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Completed |
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute |
NCT00671697 |
| Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer |
Not yet recruiting |
Skin Basal Cell Carcinoma |
NCT02699723 |
| Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia |
Terminated |
Acute Myeloid Leukemia |
NCT00513305 |
| Combination of Ibrutinib and As2O3 in the Treatment of CLL |
Unknown status |
Leukemia, Lymphocytic, Chronic, B-Cell |
NCT02757040 |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia |
Terminated |
Leukemia |
NCT00006092 |
| Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) |
Terminated |
Chronic Myelogenous Leukemia |
NCT01397734 |
| Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes |
Completed |
Leukemia|Myelodysplastic Syndromes |
NCT00274781 |
| Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery |
Active, not recruiting |
Brain and Central Nervous System Tumors |
NCT00275067 |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients |
Completed |
Multiple Myeloma|Stem Cell Transplantation |
NCT00661544 |
| Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector |
Completed |
Cancer Other Than Leukemia |
NCT01428128 |
| A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver |
Terminated |
Carcinoma, Hepatocellular |
NCT00582400 |
| Arsenic Trioxide in Treating Patients With Urothelial Cancer |
Completed |
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Transitional Cell Carcinoma of the Bladder|Ureter Cancer |
NCT00009867 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia |
Terminated |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia |
NCT00005786 |
| Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction |
Terminated |
Adenocarcinoma of the Esophagus|Stage III Esophageal Cancer|Stage IV Esophageal Cancer |
NCT00061958 |
| Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy |
Active, not recruiting |
Acute Promyelocytic Leukemia |
NCT01404949 |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients |
Not yet recruiting |
Primary Hepatocellular Carcinoma |
NCT02956772 |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations |
Not yet recruiting |
Acute Myeloid Leukemia|P53 Mutation |
NCT03381781 |
| Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia |
Terminated |
Acute Myelogenous Leukemia |
NCT00184054 |
| A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec |
Completed |
Leukemia, Other|Cancer |
NCT00250042 |
| Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors |
Completed |
Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Retinoblastoma|Sarcoma |
NCT00024258 |
| Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome |
Completed |
Myelodysplastic Syndrome |
NCT00621023 |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis |
Terminated |
Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis |
NCT01014546 |
| Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia |
Terminated |
Acute Promyelocytic Leukemia |
NCT00985530 |
| Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia |
Completed |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00258245 |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia |
Recruiting |
Acute Promyelocytic Leukemia With PML-RARA |
NCT01409161 |
| Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma |
Completed |
Refractory Multiple Myeloma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00124605 |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy |
Terminated |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes |
NCT00006220 |
| Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia |
Completed |
Leukemia |
NCT00008697 |
| Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia |
Unknown status |
Acute Promyelocytic Leukemia |
NCT00517712 |
| Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
Completed |
Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma |
NCT00045565 |
| Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine |
Completed |
Pancreatic Cancer |
NCT00053222 |
| Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Terminated |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00227682 |
| Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Completed |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma |
NCT00193518 |
| Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery |
Completed |
Liver Cancer |
NCT00128596 |
| Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML |
Completed |
Myelodysplastic Syndrome |
NCT00195104 |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide |
Completed |
Leukemia, Myeloid, Acute |
NCT00850304 |
| Arsenic Trioxide in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific |
NCT00003630 |
| Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer |
Withdrawn |
Breast Cancer |
NCT00075413 |
| Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL |
Active, not recruiting |
Acute Promyelocytic Leukemia |
NCT01987297 |
| Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00075426 |
| Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) |
Terminated |
Myelodysplastic Syndrome (MDS) |
NCT00225992 |
| Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer |
Completed |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm |
NCT00003395 |
| Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia |
Terminated |
Leukemia |
NCT00528450 |
| Arsenic Trioxide in Treating Patients With Multiple Myeloma |
Unknown status |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00017433 |
| Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer |
Completed |
Kidney Cancer |
NCT00005069 |
| Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment |
Withdrawn |
Leukemia |
NCT00006091 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease |
Terminated |
Lymphoma |
NCT00005595 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00005618 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma |
Completed |
Lymphoma |
NCT00005040 |
| Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia |
Completed |
Leukemia |
NCT00005795 |
| Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia |
Withdrawn |
Leukemia |
NCT00006090 |
| Arsenic Trioxide in Treating Men With Germ Cell Cancer |
Completed |
Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor |
NCT00036842 |
| Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma |
Unknown status |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes |
NCT00003885 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00006008 |
| Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer |
Completed |
Cervical Cancer |
NCT00005999 |
| Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes |
Unknown status |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms |
NCT00020969 |
| Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
Recruiting |
Acute Myeloid Leukemia|Relapsed/Refractory Acute Myeloid Leukemia |
NCT03318016 |
| Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma |
Completed |
Leukemia|Lymphoma |
NCT00020111 |
| Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia |
Completed |
Leukemia |
NCT00093483 |
| Acute Promyelocytic Leukemia 2006 (APL) |
Unknown status |
Leukemia, Promyelocytic, Acute |
NCT00378365 |
| Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma |
Completed |
Multiple Myeloma |
NCT00201695 |
| Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas |
Completed |
Brain and Central Nervous System Tumors |
NCT00095771 |
| Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy |
Completed |
Prostate Cancer |
NCT00004149 |
| New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia |
Withdrawn |
Acute Promyelocytic Leukemia |
NCT00670150 |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma |
Withdrawn |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00504101 |
| Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) |
Completed |
Acute Promyelocytic Leukemia |
NCT00504764 |
| Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma |
Completed |
Multiple Myeloma |
NCT00193544 |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS |
Recruiting |
P53 Mutation|Myeloid Malignancy|MDS|Aml |
NCT03855371 |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia |
Active, not recruiting |
Acute Promyelocytic Leukemia With PML-RARA |
NCT02339740 |
| Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes |
Terminated |
Myelodysplastic Syndromes |
NCT00803530 |
| Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma |
Terminated |
Multiple Myeloma |
NCT00590603 |
| Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma |
Completed |
Brain and Central Nervous System Tumors |
NCT00720564 |
| Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes |
Terminated |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms |
NCT00104806 |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes |
Terminated |
Leukemia|Myelodysplastic Syndromes |
NCT00234000 |
| Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma |
Completed |
Brain Cancer |
NCT00185861 |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
Terminated |
Leukemia|Myelodysplastic Syndromes |
NCT00118196 |
| Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes |
Completed |
Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases |
NCT00093366 |
| Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients |
Completed |
Myeloma |
NCT00469209 |
| Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00081133 |
| Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma |
Completed |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00006021 |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder |
Completed |
Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases |
NCT00274820 |
| Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00053248 |
| Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis |
Completed |
Myelofibrosis |
NCT00572065 |
| Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma |
Unknown status |
Multiple Myeloma and Plasma Cell Neoplasm |
NCT00017069 |
| A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome |
Terminated |
Myelodysplastic Syndrome |
NCT00251511 |
| Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment |
Completed |
Colorectal Cancer |
NCT00449137 |
| Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Withdrawn |
Stage II Multiple Myeloma|Stage III Multiple Myeloma|Refractory Plasma Cell Neoplasm |
NCT00085345 |
| Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J |
Completed |
Leukemia|Lymphoma |
NCT00899015 |
| The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization |
Recruiting |
Ischemic Heart Disease|Myocardial Ischemia|Coronary Disease|Acute Coronary Syndrome |
NCT02117843 |
| A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders |
Completed |
Advanced Hematological Disorders |
NCT03048344 |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma |
Withdrawn |
Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Refractory Plasma Cell Neoplasm |
NCT00112879 |
| Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic |
Unknown status |
Relapsed Acute Promyelocytic Leukemia|Refractory Acute Promyelocytic Leukemia |
NCT00196768 |
| Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia |
Completed |
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Promyelocytic Leukemia (M3)|Childhood Acute Promyelocytic Leukemia (M3)|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies |
NCT00003934 |
| Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL |
Not yet recruiting |
Acute Promyelocytic Leukaemia |
NCT04175587 |
| Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia |
Recruiting |
Acute Promyelocytic Leukemia |
NCT02688140 |
| Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL |
Completed |
Acute Promyelocytic Leukemia |
NCT00520208 |
| S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia |
Completed |
Leukemia |
NCT00551460 |
| To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization |
Active, not recruiting |
Ischemic Heart Disease|Myocardial Ischemia|Coronary Disease|Acute Coronary Syndrome |
NCT02133287 |
| Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia |
Completed |
Leukemia |
NCT00276601 |
| Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) |
Unknown status |
Leukemia |
NCT01191541 |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin |
Completed |
Acute Promyelocytic Leukemia |
NCT00413166 |
| Proteasome Inhibition in Acute Promyelocytic Leukemia |
Unknown status |
Relapsed Acute Promyelocytic Leukemia |
NCT01950611 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia |
Recruiting |
AML |
NCT03031249 |
| Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) |
Recruiting |
Acute Promyelocytic Leukemia |
NCT02899169 |
| Phase III Trial in Acute Promyelocytic Leukemia Patients |
Active, not recruiting |
Leukemia |
NCT00482833 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia |
Unknown status |
Childhood Acute Promyelocytic Leukemia (M3)|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies |
NCT00866918 |
| Leukemia SPORE Phase II 3-arm DAC Randomized Study for R/R and Elderly Acute AML and MDS |
Unknown status |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia |
NCT02190695 |
| Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy |
Unknown status |
Acute Promyelocytic Leukemia |
NCT03096496 |
| The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project |
Recruiting |
Acute Promyelocytic Leukemia |
NCT04251754 |
| Continuous Versus Intermittent cARdiac Electrical moNitorinG |
Not yet recruiting |
Torsades de Pointe Caused by Drug|Long QT Syndrome |
NCT04336644 |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia |
Completed |
Leukemia |
NCT00016159 |
| Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy |
No longer available |
CD33 Positive Acute Myelogenous Leukemia |
NCT02312037 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Completed |
Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms |
NCT02788201 |
| A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia |
Enrolling by invitation |
Childhood Acute Promyelocytic Leukemia |
NCT02200978 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes |
Completed |
Leukemia|Myelodysplastic Syndromes |
NCT00454480 |
| Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia |
Unknown status |
Acute Promyelocytic Leukemia |
NCT00675870 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
Acute Leukemia of Ambiguous Lineage|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia |
NCT02551718 |
